Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
New Trends in the Pharmacological Intervention of Ppars in Obesity: Role of Natural and Synthetic Compounds Publisher Pubmed



Nabavi SM1 ; Devi KP2 ; Sathya S2 ; Silva AS3, 4 ; Joanna L5 ; Talarek S5 ; Xu S6 ; Daglia M7, 8 ; Nabavi SF1 ; Shirooie S9, 10 ; Sureda A11, 13 ; Tejada S12, 13 ; Banach M14 ; Dehpour AR15, 16 Show All Authors
Authors
  1. Nabavi SM1
  2. Devi KP2
  3. Sathya S2
  4. Silva AS3, 4
  5. Joanna L5
  6. Talarek S5
  7. Xu S6
  8. Daglia M7, 8
  9. Nabavi SF1
  10. Shirooie S9, 10
  11. Sureda A11, 13
  12. Tejada S12, 13
  13. Banach M14
  14. Dehpour AR15, 16
  15. Saso L17

Source: Current Medicinal Chemistry Published:2021


Abstract

Obesity is a major health concern for a growing fraction of the population, as its prevalence and related metabolic disorders are not fully understood. Over the last decade, many attempts have been undertaken to understand the mechanisms at the basis of this condition, in which the accumulation of fat occurring in adipose tissue leads to the pathogenesis of obesity-related disorders. Among the most recent studies, those on Peroxisome Proliferator Activated Receptors (PPARs) revealed that these nuclear receptor proteins acting as transcription factors, among others, regulate the expression of genes involved in energy, lipid, and glucose metabolisms, and chronic inflammation. The three different isotypes of PPARs, with different tissue expression and ligand binding specificity, exert similar or overlapping functions directly or indirectly linked to obesity. In this study, we reviewed the available scientific reports concerning the PPARs structure and functions, especially in obesity, considering both natural and synthetic ligands and their role in the therapy of obesity and obesity-associated disorders. On the whole, the collected data suggest that there are both natural and synthetic compounds that show beneficial and promising activity as PPAR agonists in chronic diseases related to obesity. © 2021 Bentham Science Publishers.
Other Related Docs
10. Pparγ Gene Expression Changes in Patients With Coronary Artery Disease, Journal of Mazandaran University of Medical Sciences (2016)
13. Old and New Anti-Obesity Drugs, Journal of Diabetes and Metabolic Disorders (2025)
14. Nanoformulations of Natural Products for Management of Metabolic Syndrome, International Journal of Nanomedicine (2019)